Showing results (221-230 of 281) with videos related to

Sort By:
Pageof 29
Iscience|October 9, 2023
Spatial downregulation of CD74 signatures may drive invasive component development in part-solid lung adenocarcinomaJia-Tao Zhang, Juan Zhang, Song-Rong Wang, et al.
Journal of Cancer Research and Clinical Oncology|May 5, 2007
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerShe-Juan An, Qiang Nie, Zhi-Hong Chen, et al.
The American Journal of Surgical Pathology|October 23, 2025
Fenestrating Adenocarcinoma: A Novel Salivary Gland Cancer With EWSR1::BEND2 Fusion and Predilection for the PharynxDhuha Al-Sajee, Lisa M Rooper, Justin A Bishop, et al.
JTO Clinical and Research Reports|September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung AdenocarcinomaJia-Xin Lin, Kai Yin, Li-Xu Yan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerJin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, et al.
Annals of Surgical Oncology|May 27, 2026
The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic AnalysisYi-Fan Qi, Zhen-Bin Qiu, Wei-Ye Huang, et al.
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|December 6, 2022
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalChan-Yuan Zhang, Hao Sun, Jun-Wei Su, et al.
Pageof 29